Extensive cardiovascular and renal outcome studies have demonstrated that SGLT2 inhibitors are effective in reducing the risk of composite major adverse cardiovascular events (MACE) or attenuating the progression of chronic kidney disease (CKD) in type 2 diabetes, which is better than other glucose-lowing medications. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.